Candel Therapeutics Inc (CADL)

[georgie18]

CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...

georgie18

Member Level
Re: georgie18 post# 30885

Thursday, January 23, 2025 3:25:24 PM

Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 671947

Thursday, January 23, 2025 2:03:43 PM

Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...

georgie18

Member Level
Re: tw0122 post# 30782

Wednesday, January 22, 2025 4:45:28 PM

Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.